Publications by authors named "Winnie Chuck"
Article Synopsis
- Obesity is becoming more common in patients with inflammatory bowel disease (IBD), and this study investigates how BMI affects their response to TNF-α inhibitors (infliximab and adalimumab).
- Among 181 IBD patients, 68% experienced loss of response (LOR) to treatment, with a higher percentage observed in those with BMI ≥30 kg/m², particularly for adalimumab (83% LOR).
- The study concludes that BMI is a significant predictor of LOR for IBD patients on TNF-α inhibitors, especially with adalimumab, indicating that weight management may be crucial for treatment effectiveness.